Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Candida auris Reportable Nationally in 2019

    Candida auris Reportable Nationally in 2019

    January 1, 2019
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Candida auris Hides in Reservoir Sites, Moves Across Healthcare Continuum

    Emerging Candida auris Infects 13 in U.S.

    Emerging Candida auris Spreading in Healthcare Outbreaks

    Related Products

    Emerging Candida auris Infects 13 in U.S.

    Emerging Candida auris Spreading in Healthcare Outbreaks

    Something in Common Between Candida albicans and Staphylococcus aureus: Coagulase Production | Single Article

    Candida auris is reportable nationwide this year, a move that should boost surveillance of an emerging pathogen that has been primarily confined in three states: New York, New Jersey, and Illinois.

    The decision by the Council of State and Territorial Epidemiologists (CSTE) should put C. auris prevalence in better focus, allowing better tracking and benchmarking to measure prevention efforts. Below are some highlights and provisions from the CSTE report, which is available at: https://bit.ly/2FUtEoy.

    • “Laboratories should report suspected or confirmed cases of C. auris to State and Local Territorial [STLT] public health agencies and submit suspect C. auris isolates to regional Antibiotic Resistance Laboratory Network (AR Lab Network) laboratories or CDC via state public health laboratories for further characterization. Clinicians and healthcare facilities that become aware of a confirmed or potential case of C. auris should report the case to STLT public health authorities.”
    • “Clinical manifestation of C. auris infection depends upon the site of infection. Patients with C. auris bloodstream infection typically have sepsis and severe illness. Other invasive infections, such as intra-abdominal candidiasis, can also occur. C. auris has also been found to cause wound infections and otitis. C. auris has been found in urine and respiratory specimens, though its contribution to clinical disease in these sites is unclear. C. auris also can colonize the skin, nose, ears, and other body sites of asymptomatic people.”

    The following factors referenced in the CSTE report are aimed at helping to identify “epidemiologic linkage” in patients:

    • “Person resided within the same household with another person with confirmatory or presumptive laboratory evidence of C. auris infection or colonization.
    • OR person received care within the same healthcare facility as another person with confirmatory or presumptive laboratory evidence of C. auris infection or colonization.
    • OR person received care in a healthcare facility that commonly shares patients with another facility that had a patient with confirmatory or presumptive laboratory evidence of C. auris infection or colonization.
    • OR person had an overnight stay in a healthcare facility in the previous one year in a foreign country with documented C. auris transmission.”

    The CSTE report also details the different classifications for clinical C. auris cases:

    “Confirmed: Person with confirmatory laboratory evidence from a clinical specimen collected for the purpose of diagnosing or treating disease in the normal course of care. This includes specimens from sites reflecting invasive infection (e.g., blood, cerebrospinal fluid) and specimens from noninvasive sites such as wounds, urine, and the respiratory tract, where presence of C. auris may simply represent colonization and not true infection.

    Probable: Person with presumptive laboratory evidence and evidence of epidemiologic linkage.

    Suspect: Person with presumptive laboratory evidence and no evidence of epidemiologic linkage. Public health jurisdiction may consider stratifying clinical cases as invasive vs. noninvasive.”

    REFERENCE

    1. CSTE. Standardized Case Definition for Candida auris clinical and colonization/screening cases and National Notification of C. auris case, clinical 18-ID-05. Available at: https://bit.ly/2FUtEoy.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Hospital Infection Control & Prevention

    View PDF
    Hospital Infection Control & Prevention (Vol. 46, No. 1) - January 2019
    January 1, 2019

    Table Of Contents

    Candida auris Hides in Reservoir Sites, Moves Across Healthcare Continuum

    Candida auris Reportable Nationally in 2019

    Internet Trolls Fuel Vaccine Misinformation

    CDC Debunks Flu Shot/Pregnancy Misinformation

    Will Paralytic Syndrome Fade With Fall?

    APIC, CDC Develop Infection Cards

    Devil in the Details in CDC Infection Control Draft

    New Drugs Needed for Bad Bugs

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Peer Reviewer Patrick Joseph, MD, reports that he is a consultant for Genomic Health, Siemens, and CareDx. Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, and Editorial Group Manager Terrey L. Hatcher report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2020 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing